Browse by author
Lookup NU author(s): Dr Chris LambORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group have used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk groupings. This grid allows patients to be instructed to follow the UK Government’s advice for shielding, stringent and standard advice regarding social distancing respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
Author(s): Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok R, Powell N, Probert C, Raine T, Sebastian S, Selinger CP, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW
Publication type: Article
Publication status: Published
Print publication date: 01/06/2020
Online publication date: 17/04/2020
Acceptance date: 07/04/2020
Date deposited: 09/04/2020
ISSN (print): 0017-5749
ISSN (electronic): 1468-3288
Publisher: BMJ Group
Altmetrics provided by Altmetric